Philip Bejon/Lancet Infect Dis

COVID-19 mortality in Africa and Asia - Authors' reply.Bejon P Agweyu A Oyier I Hamaluba M Kamuya D Kinyanjui S Barasa E
Lancet Infect Dis, (2025). 25:e440

Rethinking the evidence on COVID-19 in Africa.Bejon P Agweyu A Ochola-Oyier LI Hamaluba M Kamuya D Kinyanjui S Barasa E
Lancet Infect Dis, (2025). 25:e463-e471

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.Juan-Giner A Namulwana ML Kimathi D Grantz KH Fall G Dia M Bob NS Sall AA Nerima C Sahani MK Mulogo EM Ampeire I Hombach J Nanjebe D Mwanga-Amumpaire J Cummings DAT Bejon P Warimwe GM Grais RF
Lancet Infect Dis, (2023). 23:965-973

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.Kimathi D Juan-Giner A Orindi B Grantz KH Bob NS Cheruiyot S Hamaluba M Kamau N Fall G Dia M Mosobo M Moki F Kiogora K Chirro O Thiong'o A Mwendwa J Guantai A Karanja HK Gitonga J Mugo D Ramko K Faye O Sanders EJ Grais RF Bejon P Warimwe GM
Lancet Infect Dis, (2023). 23:974-982

Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.Hamaluba M van der Pluijm RW Weya J Njuguna P Ngama M Kalume P Mwambingu G Ngetsa C Wambua J Boga M Mturi N Lal AA Khuroo A Taylor WRJ Goncalves S Miotto O Dhorda M Mutinda B Mukaka M Waithira N Hoglund RM Imwong M Tarning J Day NPJ White NJ Bejon P Dondorp AM
Lancet Infect Dis, (2021). 21:1395-1406

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.Huttner A Agnandji ST Combescure C Fernandes JF Bache EB Kabwende L Ndungu FM Brosnahan J Monath TP Lemaitre B Grillet S Botto M Engler O Portmann J Siegrist D Bejon P Silvera P Kremsner P Siegrist CA Vebcon, Vsv Ebovac Vsv-Eboplus Consortia
Lancet Infect Dis, (2018). 18:738-748

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.White MT Verity R Griffin JT Asante KP Owusu-Agyei S Greenwood B Drakeley C Gesase S Lusingu J Ansong D Adjei S Agbenyega T Ogutu B Otieno L Otieno W Agnandji ST Lell B Kremsner P Hoffman I Martinson F Kamthunzu P Tinto H Valea I Sorgho H Oneko M Otieno K Hamel MJ Salim N Mtoro A Abdulla S Aide P Sacarlal J Aponte JJ Njuguna P Marsh K Bejon P Riley EM Ghani AC
Lancet Infect Dis, (2015). 15:1450-8

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.Bejon P White MT Olotu A Bojang K Lusingu JP Salim N Otsyula NN Agnandji ST Asante KP Owusu-Agyei S Abdulla S Ghani AC
Lancet Infect Dis, (2013). 13:319-27

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.Olotu A Lusingu J Leach A Lievens M Vekemans J Msham S Lang T Gould J Dubois MC Jongert E Vansadia P Carter T Njuguna P Awuondo KO Malabeja A Abdul O Gesase S Mturi N Drakeley CJ Savarese B Villafana T Lapierre D Ballou WR Cohen J Lemnge MM Peshu N Marsh K Riley EM von Seidlein L Bejon P
Lancet Infect Dis, (2011). 11:102-9